Investor Presentation

Ref: Akums/Exchange/2026-27/60 November 02, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of investor presentation is enclosed herewith for the Earning/Quarterly conference call (group meet) going to be held on November 03, 2026, virtually. A copy of this disclosure is being updated on the website of Akums Drugs and Pharmaceuticals Limited at www.akums.in This is for your information and records Thanking You For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl: As above Q2 FY 26-27 Investor Presentation November 2026 Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Akums Drugs and Pharmaceuticals Limited. All information contained in this presentation has been prepared solely by Akums Drugs and Pharmaceuticals Limited. Akums Drugs and Pharmaceuticals Limited does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith. Managing Directors’ Message Dear Investors We are pleased to announce the results for Q2 FY27 and H1 FY27. During Q2, we enhanced the results achieved during Q1. During Q2, the revenue grew by more than 30% and EBITDA more than doubled YoY. Even sequentially i.e. QoQ, the revenue growth was at an impressive 15% and EBITDA increased by 11.5%. The growth was spearheaded by the CDMO segment with double digit volume growth and improvement in API prices. The demand environment for CDMO remains robust and Akums continues to deepen its presence within the IPM. Our domestic branded formulations segment had a steady quarter with 8% YoY growth in revenue and marked improvement in profitability on a sequential basis. Our international branded formulations business saw growth accelerating, both on YoY and QoQ basis. API segment continued on its journey towards achieving EBITDA break even as our endeavours continued. The trade generic segment cemented EBITDA positivity during the quarter. Our European CDMO project is progressing as per plan and we continue to make steady progress vis-à-vis our Zambia initiative with commercial supplies from the Indian plant scheduled during Q4 FY27 with revenue booking expected in Q1 FY 28. We are proud to announce that Akums earned an EcoVadis Bronze Medal, placing us among Top 35% of global assessed companies. We remain optimistic of delivering positive results and remain committed to creating long term shareholdervalue -Sanjeev Jain & Sandeep Jain More than Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Acquired Established R&D lab in Mumbai to Plant 1 ,2 & 3 received EU- manufacturingsite for Parabolic Drugs to Launched Akumentisto venture into regulated market. GMP accreditation OralLiquid Dosage venture intoAPI venture into branded & Sterileproducts. Listed on NSE and BSE formulations. Received US-NSF Certification Incorporated for MaxcureNutravedicsfacility Set up dedicated Started new injectable and in April 2004 Established a Started dedicated plant anew OSD facility facility for Penemsat nutraceutical for β-lactam anti- Kotdwar Set up of first facility infectives and steroids ANVISAcertified for Plant 3 plant for oral soliddosage Acquired 2 plants in form in Cosmetics and Haridwar. nutraceuticals Technologically Advanced Manufacturing Capabilities (1/2) Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar YEAR 2004 2007 2007 2010 2010 2010 2014 CAPACITY¹ 649 15 39 264 6 269 2,635 Ayurvedic / CAPABILITY General General General Hormonal Cosmetics General Nutraceuticals DOSAGE FORMS 1 2 3 1 3 4 4 1 2 1 2 3 4 DOSAGE FORM 1 Oral solid 2 Oral liquid 3 Injectable / sterile 4 External / topical ¹ Annual capacity in Cr units Technologically Advanced Manufacturing Capabilities (2/2) PHOTO PHOTO Location Haridwar Kotdwar Baddi Haridwar Roorkee Noida Baddi# YEAR 2014 2021 2023 2024 2026 2026 2027 CAPACITY¹ 732 17 392 41 13 7 - β-lactams & Penem CAPABILITY General General Cosmeceuticals Cosmeceuticals General steroids anti-infective DOSAGE FORMS 1 2 3 4 1 2 3 1 2 3 1 4 4 1 QUALITY CREDENTIALS* DOSAGE FORM 1 Oral solid 2 Oral liquid 3 Injectable / sterile 4 External / topical *Received by some or all facilities; # upcoming facility; ¹ Annual capacity in Cr units Q2/H1 FY 27 Financial Performance Highlights Key drivers as well as their trends during Q2 FY27 Key drivers and their impact on Akums’ performance Marketing Strong CDMO API segment API prices saw segments volume growth continues on its an increase in profitability momentum path to Q2 improved continues profitability sequentially International and domestic Akums continued to witness branded segments margins double digit volume growth API prices momentum sustained API losses curtailed significantly. remained lower YoY however, leading to healthy capacity in Q2 albeit at a lower pace. improved sequentially. Trade utilization over 50%. generics continues to break even. Q2 FY27 Performance Highlights Consolidated Performance Segment Break-up Business Vertical Share in revenue 224 cr 115 cr CDMO 83.1% 121 cr 54 cr 1,371 cr 16.3% 8.4% 1,050 cr Domestic Branded Formulation 9.8% 11.6% 5.1% Total Income EBITDA (including PAT International Branded Formulation 3.3% To(t+a3l0 I.n6c%o mYoeY ) oAthdej.r E inBcIToDmAe) (+1A6d8j.3. P%A YToY) (+0.3% YoY) (-(1+3706 .b3p%s YYooYY)) (-57 bps YoY) API 2.1% Trade Generics 1.7% Operating Performance 115 cr 195 cr 1,342 cr 8.4% 14.5% Revenue EBITDA PAT (+31.9% YoY) (+106.1% YoY) (+168.3% YoY) H1 FY27 Performance Highlights Consolidated Performance Segment Break-up Business Vertical Share in revenue 429 cr 216 cr CDMO 82.9% 121 cr 54 cr 2,568 cr 16.7% 8.4% 1,050 cr Domestic Branded Formulation 9.9% 11.6% 5.1% Total Income EBITDA (including PAT International Branded Formulation 3.1% To(t+a2l2 I.n3c%o YmoeY ) oAthdej.r E inBcIToDmAe) (+1A0d0j.7. P%A YToY) (+0.3% YoY) (-(1+3501 .b7%ps Y YooYY)) (-57 bps YoY) API 2.4% Trade Generics 1.8% Operating Performance 216 cr 369 cr 2,509 cr 8.4% 14.7% Revenue EBITDA PAT (+22.9% YoY) (+65.3% YoY) (+100.7% YoY) Profit and Loss Statement Particulars (Rs Cr) Q2 FY27 Q2 FY26 Y-O-Y (%) Q1 FY27 Q-O-Q (%) H1 FY 27 H1 FY 26 Y-O-Y (%) FY26 Revenue 1,342 1,018 31.9% 1,167 15.1% 2,509 2,042 22.9% 4,359 COGS 767 593 29.4% 645 18.8% 1,412 1,174 20.2% 2,514 GP Margin % 42.9% 41.8% 44.7% 43.7% 42.5% 42.3% Employee Expenses 224 189 18.5% 201 11.3% 426 365 16.5% 754 Other Expenses 157 141 10.9% 145 8.0% 302 278 8.5% 570 EBITDA 195 94 106.1% 175 11.5% 369 223 65.3% 522 EBITDA Margin % 14.5% 9.3% 15.0% 14.7% 10.9% 12.0% Finance Cost 26 23 10.2% 25 3.7% 50 46 8.6% 94 Depreciation & Amort. 43 38 14.1% 41 5.2% 84 75 12.7% 155 Exceptional Expenses - - - - - - - - 20 Other Income 29 32 (10.7)% 30 (4.9)% 59 59 0.3% 129 Profit Before Tax 155 66 135.6% 139 11.1% 294 161 82.2% 382 Tax 40 23 74.9% 38 5.0% 78 54 45.4% 126 PAT 115 43 168.3% 101 13.5% 216 107 100.7% 256 PAT Margin % 8.4% 4.1% 8.4% [Showing first 8,000 characters — download PDF for full document]